Invicta Medical
- Industry
- Medical Technology
- Founded Year
- 2013
- Headquarters
- Santa Clara, California, United States
- Employee Count
- 21
Key People
- Rick O'Connor - Chief Executive Officer
- Nancy Gallo - SVP Clinical & Regulatory
- Chris Mora - VP Business & Strategy
- Dennis Potts - Vice President of Engineering
- Tim Fayram - Vice President of Clinical Research
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a track record in medical technology.
Rick O'Connor, the CEO, has considerable experience introducing disruptive, world-class therapies to market. The team includes seasoned professionals in clinical and regulatory affairs, business strategy, engineering, and clinical research, indicating a strong foundation for the company's endeavors.
- Clinical Need
-
Aspect: Very Strong
Summary: Obstructive sleep apnea (OSA) affects millions globally, with existing therapies often being inadequate.
OSA is estimated to affect 425 million people worldwide, with many patients remaining undertreated due to the limitations of current therapies. Invicta Medical's innovative approach aims to address these shortcomings, offering a potentially transformative solution.
- Competition
-
Aspect: Somewhat crowded
Summary: The sleep apnea treatment market has several existing players, but opportunities for innovation remain.
The market includes established therapies like CPAP machines and other neurostimulation devices. However, Invicta Medical's minimally invasive, injectable solution offers a novel alternative that could differentiate it from competitors.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a minimally invasive, injectable neurostimulation device presents technical challenges.
Creating a device that is both effective and minimally invasive requires overcoming significant engineering and medical challenges. Ensuring consistent performance and patient safety are critical factors that need to be addressed.
- Patent
-
Aspect: Very Strong
Summary: The company holds a robust intellectual property portfolio with numerous patents.
Invicta Medical has secured 35 patents and patents pending, covering various aspects of their technology. This extensive IP protection enhances the company's position in the market and deters potential competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has successfully raised significant funding from reputable investors.
Invicta Medical completed a $25 million Series A financing led by Forepont Capital, with participation from several other prominent investors. This funding enables the company to advance its product development and move towards market entry.
- Regulatory
-
Aspect: Running FIH
Summary: The company is conducting first-in-human trials to validate its therapy.
Invicta Medical is in the process of conducting clinical studies to demonstrate the safety and efficacy of its therapy. Successful completion of these trials is essential for obtaining regulatory approval and subsequent commercialization.
Opportunity Rollup
- Odds of Success
- 4.3
- Peak Market Share
- 5.95
- Segment CAGR
- 3.4%
- Market Segment
- Medical Devices
- Market Sub Segment
- Sleep Apnea Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.30 |
| 2 | 0.89 |
| 3 | 2.08 |
| 4 | 4.16 |
| 5 | 5.95 |
Key Takeaway
Invicta Medical's innovative, minimally invasive neurostimulation therapy addresses a significant unmet need in sleep apnea treatment, supported by a strong team and robust funding.